July 23rd 2025
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety
Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies
Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab